Please assess the completion status of the following clinical trial:

Trial Title: Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Residing in or around Pondicherry and adjoining Tamilnadu areas~* Night blood microfilaria counts \> 10 mf/ml by membrane filtration~* No history of treatment for filarial infection for the last two years at least~* Willing for home visits by the staff of the center~* Willing to give written informed consent~Exclusion Criteria:~* Body weight less than 30 kg~* Hepatic or renal disease as evidenced by clinical or biochemical abnormalities. - concurrent illness like hypertension, diabetes mellitus, cardiac conditions and epilepsy requiring chronic medication~* Psychiatric illness~* Patients under tetracycline or doxycycline therapy~* History of de-worming by albendazole or other anti-helminthic during last one year~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- DEC + ALB sequential (Type: EXPERIMENTAL): Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet at 30 days post treatment sequentially
- DEC + ALB co-admin (Type: EXPERIMENTAL): Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet per day given orally as single dose for 12 days
- DEC + DOXY co-admin (Type: EXPERIMENTAL): Diethylcarbamazine 300 mg tablet and Doxycycline 100 mg per day given orally as single dose for 12 days
- Diethylcarbamazine (DEC) (Type: ACTIVE_COMPARATOR): Diethylcarbamazine 300 mg tablet as single dose orally per day for 12 days

Based on this trial design, predict the completion outcome and termination type (if applicable).